AU2004274474B2 - Thalidomide analogs as TNF-alpha modulators - Google Patents

Thalidomide analogs as TNF-alpha modulators Download PDF

Info

Publication number
AU2004274474B2
AU2004274474B2 AU2004274474A AU2004274474A AU2004274474B2 AU 2004274474 B2 AU2004274474 B2 AU 2004274474B2 AU 2004274474 A AU2004274474 A AU 2004274474A AU 2004274474 A AU2004274474 A AU 2004274474A AU 2004274474 B2 AU2004274474 B2 AU 2004274474B2
Authority
AU
Australia
Prior art keywords
compound
substituted
sulfur
alkyl
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004274474A
Other languages
English (en)
Other versions
AU2004274474A1 (en
Inventor
Arnold Brossi
William D. Figg
Tony Giordano
Nigel H. Greig
Harold Holloway
Qian-Sheng Yu
Xiaoxiang Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2004274474A1 publication Critical patent/AU2004274474A1/en
Assigned to GIORDANO, TONY, BROSSI, ARNOLD, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment GIORDANO, TONY Amend patent request/document other than specification (104) Assignors: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Application granted granted Critical
Publication of AU2004274474B2 publication Critical patent/AU2004274474B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2004274474A 2003-09-17 2004-09-17 Thalidomide analogs as TNF-alpha modulators Ceased AU2004274474B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50472403P 2003-09-17 2003-09-17
US60/504,724 2003-09-17
PCT/US2004/030506 WO2005028436A2 (en) 2003-09-17 2004-09-17 Thalidomide analogs as tnf-alpha modulators

Publications (2)

Publication Number Publication Date
AU2004274474A1 AU2004274474A1 (en) 2005-03-31
AU2004274474B2 true AU2004274474B2 (en) 2011-03-10

Family

ID=34375538

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004274474A Ceased AU2004274474B2 (en) 2003-09-17 2004-09-17 Thalidomide analogs as TNF-alpha modulators

Country Status (9)

Country Link
US (2) US7973057B2 (OSRAM)
EP (1) EP1663223B1 (OSRAM)
JP (1) JP4943845B2 (OSRAM)
CN (1) CN1867331B (OSRAM)
AU (1) AU2004274474B2 (OSRAM)
BR (1) BRPI0414497A (OSRAM)
CA (2) CA2808646C (OSRAM)
SG (1) SG133603A1 (OSRAM)
WO (1) WO2005028436A2 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2929331B2 (ja) * 1990-07-18 1999-08-03 丸善石油化学株式会社 トラクションドライブ用流体
CN103880827B (zh) 2004-07-15 2017-01-04 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CA2660806C (en) * 2006-08-30 2015-06-16 Celgene Corporation 5-substituted isoindoline compounds
AU2013260742B2 (en) * 2007-03-20 2016-06-16 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
CN103641814A (zh) * 2007-03-20 2014-03-19 细胞基因公司 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法
US7723301B2 (en) * 2007-08-29 2010-05-25 The Board Of Trustees Of The University Of Arkansas Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
KR101830447B1 (ko) * 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
ES2664872T3 (es) * 2010-06-18 2018-04-23 Taiho Pharmaceutical Co., Ltd Moduladores PRPK-TPRKB y sus usos
US8927725B2 (en) * 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
JP2015500001A (ja) 2011-12-14 2015-01-05 大鵬薬品工業株式会社 組換えｐｒｐｋ−ｔｐｒｋｂ及びその使用
US9383644B2 (en) 2014-09-18 2016-07-05 Heraeus Precious Metals North America Daychem LLC Sulfonic acid derivative compounds as photoacid generators in resist applications
ES2812877T3 (es) 2014-10-30 2021-03-18 Kangpu Biopharmaceuticals Ltd Derivado de isoindolina, producto intermedio, método de preparación, composición farmacéutica y uso del mismo
US9477150B2 (en) 2015-03-13 2016-10-25 Heraeus Precious Metals North America Daychem LLC Sulfonic acid derivative compounds as photoacid generators in resist applications
CA2991529C (en) * 2015-07-08 2021-01-05 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment
EP3356346B1 (en) 2015-09-30 2024-11-06 THE UNITED STATES OF AMERICA, as represented by the Secretary, DEPARTMENT OF HEALTH AND HUMAN SERVICES Thalidomide analogs and methods of use
US11395820B2 (en) 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
JP7143295B2 (ja) * 2016-11-24 2022-09-28 ティアンジン ヘメイ ファーマスーティカル サイ－テック カンパニー リミテッド ピペリジン－２，６－ジオン誘導体及びクローン病の治療
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
US11730726B2 (en) 2018-07-11 2023-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
US11324731B2 (en) 2018-09-13 2022-05-10 City Of Hope TXNIP-TRX complex inhibitors and methods of using the same
EP3880669A1 (en) 2018-11-13 2021-09-22 Biotheryx, Inc. Substituted isoindolinones
WO2020124500A1 (zh) * 2018-12-20 2020-06-25 江苏凯迪恩医药科技有限公司 一种含氮杂环化合物、其制备方法及应用
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
CN114641337A (zh) * 2019-08-27 2022-06-17 密歇根大学董事会 Cereblon e3连接酶抑制剂
KR102783667B1 (ko) 2019-10-24 2025-03-21 삼성전자 주식회사 전자 장치 및 그의 디스플레이 동작 제어 방법
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
TW202140448A (zh) * 2020-01-16 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用
US20230096517A1 (en) * 2020-02-25 2023-03-30 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
KR20220055171A (ko) * 2020-10-26 2022-05-03 주식회사 아이비스바이오 포말리도마이드로부터 3,6'-디티오포말리도마이드를 선택적으로 합성하는 방법
US20240166647A1 (en) * 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
JP2025508863A (ja) 2022-02-25 2025-04-10 アイヴィス バイオ インコーポレーテッド 新規のポマリドミド誘導体の脳疾患治療用途
AR130961A1 (es) * 2022-11-04 2025-02-05 Bristol Myers Squibb Co Compuestos y su uso para el tratamiento de hemoglobinopatías
CN119654316A (zh) * 2023-07-14 2025-03-18 标新生物医药科技(上海)有限公司 基于硫代的戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1049283A (en) * 1962-04-14 1966-11-23 Distillers Co Yeast Ltd Substituted butyro-lactones and -thiolactones
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3794641A (en) * 1970-11-10 1974-02-26 Nehezvegyipari Kutato Intezet Substituted phthalimido-1,3,5-triazines
US5593990A (en) * 1993-03-01 1997-01-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
WO2002068414A2 (en) * 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830991A (en) 1954-05-17 1958-04-15 Gruenenthal Chemie Products of the amino-piperidine-2-6-dione series
GB962857A (en) 1961-12-04 1964-07-08 Distillers Co Yeast Ltd Process for the production of imides
US3314953A (en) 1964-03-16 1967-04-18 Richardson Merrell Inc 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines
IL25595A (en) 1965-05-08 1971-01-28 Gruenenthal Chemie New history of cyclic amide compounds and process for the production of these compounds
US3560495A (en) 1965-05-08 1971-02-02 Ernst Frankus 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
US4067718A (en) 1975-11-12 1978-01-10 American Cyanamid Company Method for controlling the relative stem growth of plants
US4291048A (en) 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
US5354690A (en) 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
GB9311281D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
ES2098505T3 (es) 1991-04-17 1997-05-01 Gruenenthal Chemie Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
US6096768A (en) 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5443824A (en) 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
DE4422237A1 (de) 1994-06-24 1996-01-04 Gruenenthal Gmbh Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
ATE200621T1 (de) 1994-12-30 2001-05-15 Celgene Corp Immunotherapeutische imide/amide und ihre verwendung zur verminderung des tnfalpha-spiegels
US5783605A (en) 1995-02-27 1998-07-21 Kuo; Sheng-Chu Helper inducers for differentiation therapy and chemoprevention of cancer
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
DE19613976C1 (de) 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
CA2251060C (en) 1996-04-09 2006-09-12 Grunenthal Gmbh Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
EP0914123A4 (en) 1996-05-29 2000-10-11 Prototek Inc THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE69717831T3 (de) 1996-07-24 2018-08-30 Celgene Corp. Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
DE69734290T2 (de) 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
HUP0000288A3 (en) 1996-12-13 2001-04-28 Lilly Co Eli Azetidinone derivatives as inhibitors of the enzymatic activity of psa, intermediates, process for their preparation and pharmaceutical compositions thereof
DE19703763C1 (de) 1997-02-01 1998-10-01 Gruenenthal Gmbh Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
RU2108786C1 (ru) 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
DE19743968C2 (de) 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
WO1999058096A2 (en) 1998-05-11 1999-11-18 Entremed, Inc. Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
AU748397B2 (en) 1998-05-15 2002-06-06 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
DE19843793C2 (de) 1998-09-24 2000-08-03 Gruenenthal Gmbh Substituierte Benzamide
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
SI1040838T1 (en) 1999-03-31 2003-08-31 Gruenenthal Gmbh Stable aqueous solution of 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2001041755A2 (en) 1999-12-02 2001-06-14 The Regents Of The University Of Michigan Topical compositions comprising thalidomide for the treatment of inflammatory diseases
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
ATE374609T1 (de) 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
ATE428419T1 (de) 2001-08-06 2009-05-15 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
CA2672000C (en) 2002-05-17 2011-11-29 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma
CN100488959C (zh) 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1049283A (en) * 1962-04-14 1966-11-23 Distillers Co Yeast Ltd Substituted butyro-lactones and -thiolactones
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3794641A (en) * 1970-11-10 1974-02-26 Nehezvegyipari Kutato Intezet Substituted phthalimido-1,3,5-triazines
US5593990A (en) * 1993-03-01 1997-01-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
WO2002068414A2 (en) * 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAY, B. L. et al. Tetrahedron Letters (1995), 36(25), 4483-4486 *
HASHIMOTO, Y. Bioorganic & Medicinal Chemistry (2002), 10, 461-479 *
ORZESZKO, A. et al. Il Farmaco (2003), 58, 371-376 *
SHIMAZAWA, R. et al. Biol. Pharm. Bull. (1999), 22(2), 224-226 *

Also Published As

Publication number Publication date
CN1867331B (zh) 2010-05-26
US20110245210A1 (en) 2011-10-06
SG133603A1 (en) 2007-07-30
WO2005028436A2 (en) 2005-03-31
US8546430B2 (en) 2013-10-01
JP2007505922A (ja) 2007-03-15
CA2808646C (en) 2016-08-23
US7973057B2 (en) 2011-07-05
EP1663223A2 (en) 2006-06-07
CN1867331A (zh) 2006-11-22
JP4943845B2 (ja) 2012-05-30
US20060211728A1 (en) 2006-09-21
CA2808646A1 (en) 2005-03-31
WO2005028436A3 (en) 2005-05-19
CA2538864C (en) 2013-05-07
AU2004274474A1 (en) 2005-03-31
EP1663223B1 (en) 2014-01-01
CA2538864A1 (en) 2005-03-31
BRPI0414497A (pt) 2006-11-14

Similar Documents

Publication Publication Date Title
AU2004274474B2 (en) Thalidomide analogs as TNF-alpha modulators
US8853253B2 (en) Thalidomide analogs
US10220028B2 (en) Thio compounds
CN112969696B (zh) 乙酰化书写器抑制剂的开发及其用途
JP6806969B2 (ja) 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物
CA2433021C (en) Isoindole-imide compounds, compositions, and uses thereof
JP5156378B2 (ja) ＭＤＭ２とｐ５３の間の相互作用の阻害剤
CA2425440C (en) Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
JP2023547084A (ja) アンドロゲン受容体タンパク質の標的分解のための化合物および方法
KR20110098827A (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
CA3215907A1 (en) Substituted 2-(2,6-dioxopiperidin-3-yl)-5-(1-piperidin-4-yl)isoindoline-1,3-dione derivatives and uses thereof
CN105793242B (zh) 苯氧基乙基环状胺衍生物及其作为ep4受体调节剂的活性
PT1497019E (pt) Compostos de pirrolotriazina anilina úteis como inibidores de quinase
KR102404865B1 (ko) 항종양제
CN100418965C (zh) 咪唑并吡啶衍生物
WO2004035581A1 (ja) スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤
JP2024532119A (ja) Ｃｃｒ６阻害剤としてのアリールスルホニル化合物
MX2014011998A (es) Compuestos carboxamida y su uso como inhibidores de calpaína v.
GB2355457A (en) Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
WO2006129679A1 (ja) スピロピペリジン化合物およびその医薬用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired